Somewhat Positive Media Coverage Somewhat Unlikely to Affect Dova Pharmaceuticals (DOVA) Stock Price
Press coverage about Dova Pharmaceuticals (NASDAQ:DOVA) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Dova Pharmaceuticals earned a news impact score of 0.20 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.5711781359347 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Shares of Dova Pharmaceuticals (NASDAQ:DOVA) traded up 2.18% on Monday, reaching $25.34. The company’s stock had a trading volume of 90,670 shares. Dova Pharmaceuticals has a 52-week low of $16.98 and a 52-week high of $29.99. The firm’s 50 day moving average is $26.24 and its 200-day moving average is $24.40. The stock’s market cap is $650.02 million.
Dova Pharmaceuticals (NASDAQ:DOVA) last announced its quarterly earnings results on Thursday, August 10th. The company reported ($0.32) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.08). On average, equities research analysts forecast that Dova Pharmaceuticals will post ($1.40) EPS for the current year.
A number of research analysts have commented on the company. J P Morgan Chase & Co assumed coverage on Dova Pharmaceuticals in a report on Monday, July 24th. They issued an “overweight” rating and a $35.00 price objective on the stock. Leerink Swann raised Dova Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $32.00 price objective on the stock in a report on Tuesday, September 26th. Jefferies Group LLC assumed coverage on Dova Pharmaceuticals in a report on Monday, July 24th. They issued a “buy” rating and a $30.00 price objective on the stock. Finally, Zacks Investment Research raised Dova Pharmaceuticals from a “hold” rating to a “buy” rating and set a $31.00 price objective on the stock in a report on Wednesday, October 11th.
In related news, Director Steven M. Goldman purchased 20,169 shares of Dova Pharmaceuticals stock in a transaction dated Tuesday, August 15th. The stock was bought at an average cost of $22.23 per share, for a total transaction of $448,356.87. Following the completion of the transaction, the director now owns 81,158 shares in the company, valued at $1,804,142.34. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Paul B. Manning purchased 25,870 shares of Dova Pharmaceuticals stock in a transaction dated Wednesday, August 16th. The stock was bought at an average price of $22.30 per share, with a total value of $576,901.00. The disclosure for this purchase can be found here.
About Dova Pharmaceuticals
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
Receive News & Ratings for Dova Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.